Stockscreener 앱 받기
8.80
6.28%
0.52
시간 외 거래:
8.87
0.07
+0.80%
전일 마감가:
$8.28
열려 있는:
$8.6
하루 거래량:
2.67M
Relative Volume:
2.22
시가총액:
$946.61M
수익:
$247.00M
순이익/손실:
$-249.00M
주가수익비율:
-2.8479
EPS:
-3.09
순현금흐름:
$-267.00M
1주 성능:
-1.57%
1개월 성능:
+7.58%
6개월 성능:
-47.53%
1년 성능:
-47.34%
1일 변동 폭
$8.51
$9.00
1주일 범위
$7.06
$9.00
52주 변동 폭
$6.50
$18.98
Arcus Biosciences Inc Stock (RCUS) Company Profile
명칭
Arcus Biosciences Inc
전화
(510) 694-6200
주소
3928 POINT EDEN WAY, HAYWARD, CA
RCUS을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
RCUS
Arcus Biosciences Inc
|
8.80 | 946.61M | 247.00M | -249.00M | -267.00M | -3.09 |
|
VRTX
Vertex Pharmaceuticals Inc
|
439.37 | 128.45B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
575.63 | 65.17B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
560.90 | 40.09B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
270.19 | 35.67B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ONC
Beigene Ltd Adr
|
233.25 | 27.44B | 3.81B | -644.79M | -669.77M | -6.24 |
Arcus Biosciences Inc Stock (RCUS) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-02-26 | 업그레이드 | H.C. Wainwright | Neutral → Buy |
| 2024-10-21 | 개시 | H.C. Wainwright | Neutral |
| 2024-10-08 | 개시 | Wells Fargo | Overweight |
| 2022-11-18 | 개시 | BofA Securities | Neutral |
| 2022-10-11 | 개시 | Morgan Stanley | Overweight |
| 2021-10-15 | 재개 | BTIG Research | Buy |
| 2020-11-24 | 개시 | Berenberg | Buy |
| 2020-11-23 | 개시 | Evercore ISI | Outperform |
| 2020-04-03 | 개시 | Cantor Fitzgerald | Overweight |
| 2020-03-04 | 개시 | Barclays | Overweight |
| 2019-11-12 | 개시 | SunTrust | Buy |
| 2019-09-27 | 개시 | Mizuho | Buy |
| 2019-05-24 | 재개 | Citigroup | Buy |
| 2018-10-09 | 개시 | Wedbush | Outperform |
| 2018-04-09 | 개시 | Citigroup | Buy |
| 2018-04-09 | 개시 | Goldman | Neutral |
| 2018-04-09 | 개시 | Leerink Partners | Outperform |
모두보기
Arcus Biosciences Inc 주식(RCUS)의 최신 뉴스
First Trust Advisors LP Has $264,000 Stock Holdings in Arcus Biosciences, Inc. (NYSE:RCUS) - Defense World
Arcus Biosciences Announces New Employment Inducement Grants | R - GuruFocus
Arcus Biosciences (RCUS): Morgan Stanley Lowers Price Target | R - GuruFocus
Arcus Biosciences Announces New Employment Inducement Grants - Business Wire
Raymond James Financial Inc. Makes New Investment in Arcus Biosciences, Inc. (NYSE:RCUS) - Defense World
Morgan Stanley Lowers Price Target on Arcus Biosciences to $22 From $24, Keeps Overweight Rating - marketscreener.com
Goldman Sachs Adjusts Price Target for Arcus Biosciences (RCUS) | RCUS Stock News - GuruFocus
Wells Fargo Adjusts Price Target for Arcus Biosciences (RCUS) to $26 | RCUS Stock News - GuruFocus
Arcus Biosciences First Quarter 2025 Earnings: Misses Expectations - Yahoo Finance
Arcus Biosciences (RCUS) Receives Adjusted Price Target from Wel - GuruFocus
Analyzing Ratios: Arcus Biosciences Inc (RCUS)’s Financial Story Unveiled - DWinneX
European regulators to review Valneva shot; Jazz's stock dips on subpar first-quarter revenue - Endpoints News
Arcus Biosciences, Inc. (NYSE:RCUS) Q1 2025 Earnings Call Transcript - MSN
Arcus Biosciences (RCUS) Receives Adjusted Price Target from Wells Fargo | RCUS Stock News - GuruFocus
Arcus Biosciences, Inc. (NYSE:RCUS) Shares Purchased by Dimensional Fund Advisors LP - Defense World
Arcus Biosciences Q1 2025 Earnings Call Transcript - MarketBeat
Arcus Biosciences Inc (RCUS) Q1 2025 Earnings Call Highlights: Strategic Focus and Financial ... - Yahoo Finance
Arcus Biosciences earnings missed by $0.12, revenue fell short of estimates - Investing.com Canada
Earnings call transcript: Arcus Biosciences Q1 2025 misses earnings estimates - Investing.com
Arcus Biosciences, Inc. (RCUS) Reports Q1 Loss, Lags Revenue Estimates - Yahoo Finance
Earnings call transcript: Arcus Biosciences Q1 2025 misses earnings estimates By Investing.com - Investing.com India
Arcus Biosciences Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Arcus Biosciences (RCUS) Misses Q1 Revenue Expectations, Outlines Future Plans | RCUS Stock News - GuruFocus
Arcus Biosciences Q1 2025 Earnings: EPS Misses at -$1.14, Revenue Falls Short at $28 Million - GuruFocus
Arcus Biosciences Q2 2025 slides: advancing late-stage oncology pipeline with $1B cash - Investing.com Canada
Arcus Cancer Drug Shows Breakthrough 30% Response Rate in Kidney Cancer Trial, Reports Strong Q1 Earnings - Stock Titan
Earnings To Watch: Arcus Biosciences Inc (RCUS) Reports Q1 2025 Result - GuruFocus
Renaissance Technologies LLC Lowers Stock Holdings in Arcus Biosciences, Inc. (NYSE:RCUS) - Defense World
Arcus Biosciences, Inc.'s (NYSE:RCUS) Shares Bounce 33% But Its Business Still Trails The Industry - simplywall.st
Arcus Biosciences, Inc. (NYSE:RCUS) Receives Average Recommendation of “Buy” from Brokerages - Defense World
Long Term Trading Analysis for (RCUS) - news.stocktradersdaily.com
Wells Fargo & Company MN Has $575,000 Position in Arcus Biosciences, Inc. (NYSE:RCUS) - Defense World
Taking the lead: Arcus Biosciences Inc (RCUS) - Sete News
Arcus Biosciences Inc (RCUS) Stock: Navigating a Year of Volatility - investchronicle.com
Can you now get a good deal on Arcus Biosciences Inc’s shares? - uspostnews.com
Arcus Biosciences Inc [RCUS] Investment Guide: What You Need to Know - knoxdaily.com
Arcus Biosciences Inc (NYSE: RCUS) Could Soar To Much Higher Prices In Coming Months - Marketing Sentinel
Arcus Biosciences, Inc. (NYSE:RCUS) Shares Bought by Invesco Ltd. - Defense World
Barclays Cuts Arcus Biosciences (NYSE:RCUS) Price Target to $14.00 - Defense World
Arcus Biosciences Announces New Employment Inducement Grants | RCUS Stock News - GuruFocus
RCUSArcus Bioscience Latest Stock News & Market Updates - Stock Titan
Are Arcus Biosciences Inc (RCUS) shares a good deal now? - uspostnews.com
Russell Investments Group Ltd. Raises Position in Arcus Biosciences, Inc. (NYSE:RCUS) - Defense World
Arcus Biosciences to Present First Combination Data for HIF-2a I - GuruFocus
Arcus Biosciences to Present First Combination Data for HIF-2a Inhibitor Casdatifan Plus Cabozantinib in an Oral Presentation at the 2025 ASCO Annual Meeting | RCUS Stock News - GuruFocus
Groundbreaking Kidney Cancer Treatment Data: Arcus Reveals First Casdatifan-Cabozantinib Results at ASCO 2025 - Stock Titan
Arcus Biosciences Inc (RCUS) Is A Buy According To Analysts - Marketing Sentinel
Forecasting The Future: 5 Analyst Projections For Arcus Biosciences - Benzinga
Arcus Biosciences (RCUS) Price Target Slashed by Barclays to $14 - GuruFocus
Arcus Biosciences to Host Conference Call to Discuss First-Quarter 2025 Financial Results and Pipeline Update | RCUS Stock News - GuruFocus
Arcus Biosciences to Host Conference Call to Discuss First-Quarter 2025 Financial Results and Pipeline Update - Business Wire
Arcus Biosciences Inc (RCUS) 재무 분석
매출
순이익
현금흐름
주당 순 이익
4.10%
자본화:
|
볼륨(24시간):